Loading
NA
Newcourt Acquisition Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 26 Oct 2021.
Newcourt Acquisition Corp: what insiders have been doing
Newcourt Acquisition Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Newcourt Acquisition Corp has published a filing in the past twelve months. The most recent one dates from 16 January 2024.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€37,327
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net incomeUS$6.9M
Last declaration on 16 January 2024
Declarations4 total
7,455,000 sharesClass A Ordinary Shares, par value $0.0001SEC:0001104659-24-004171:0
130,000 shares@ US$11.07100.0% of flowClass A ordinary shares, par value $0.0001 per share, includSEC:0001326389-23-000799:0
3,749 shares@ US$10.58100.0% of flowCommon StockSEC:0001209191-23-017433:0
920,000 sharesClass A Ordinary Shares, par value $0.0001SEC:0001104659-21-129890:0
Canonical exit: 20 Jan 2022 (T+90)
4 of 4 declarations
About Newcourt Acquisition Corp
Newcourt Acquisition Corp is a US-listed SPAC traded on the NASDAQ in the United States. It was incorporated on February 25, 2021 in the Cayman Islands, and was formed not to run a traditional operating business, but to pursue a merger, share exchange, asset acquisition, recapitalization, reorganization, or similar business combination with one or more private companies. For investors, that means the equity story is fundamentally event-driven: the company’s value is tied to deal execution, target quality, and the eventual economics of any announced combination. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000110465921122965/tm219717-16_s1a.htm?utm_source=openai))
From an analytical standpoint, Newcourt’s business model is that of a capital-markets vehicle rather than a product company. SEC filings describe the company as a blank-check entity with no initial restriction to a specific industry or geographic region, which gave management broad discretion in target selection. Recent SEC materials also identify an Oakland, California address, which provides the operating base in the United States even though the issuer’s original formation jurisdiction was the Cayman Islands. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000141057823002572/ncacu-20230930x10q.htm?utm_source=openai))
Read moreShow less
Because Newcourt is a SPAC, it does not have conventional operating segments such as manufacturing, distribution, or recurring service lines. Its “core product” is access to public markets through a business combination. The competitive positioning therefore depends on sponsor credibility, the attractiveness of the target, the structure of the merger, and the ability to satisfy closing conditions. In a crowded SPAC landscape, the key differentiators are often transaction discipline, financing certainty, and the market’s willingness to accept the combined company’s long-term growth profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000141057823002572/ncacu-20230930x10q.htm?utm_source=openai))
The most important recent development is the announced business combination with Psyence Group Inc. and Psyence Biomed, a biotechnology company focused on natural psilocybin-based solutions for mental health and palliative care. Newcourt announced the definitive agreement on January 9, 2023, and later SEC-related updates in 2024 indicated that closing conditions had not yet been satisfied at that time. That effectively shifts the investment narrative toward Health & Pharma, because the post-transaction equity case is expected to be driven by a life-science platform rather than by Newcourt’s original SPAC structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000110465923002364/tm232749d2_ex99-1.htm?utm_source=openai))
